M.D. Anderson Cancer Center
To find the recommended doses of lisaftoclax and olverembatinib that can be given in combination with decitabine to participants with advanced CML and Ph+ AML.
Primary Objectives • To establish the minimum safe and biologically-effective dose of lisaftoclax and olverembatinib in combination with decitabine Secondary Objectives * To determine the rate of conversion to CML-CP for participants with advanced phase CML or complete remission (CR)/CR with incomplete hematology recovery (CRi) for participants with Ph+ AML, within 4 cycles of combination therapy * To assess other efficacy endpoints (CR rate, measurable residual disease negativity by flow cytometry, rates of CCyR, MMR, MR4 and MR4.5, relapse-free survival, overall survival) * To assess prop…
Inclusion Criteria: a) Diagnosis: Age ≥18 years with CML-AP, CML-MBP, or Ph+ AML by WHO 2016 criteria. * Participants must have been intolerant or resistant to at least one prior BCR::ABL1 TKI 2\. Performance status ≤3 (ECOG Scale). 3\. Adequate liver, cardiac, renal and pancreatic function as defined by the following criteria: 1. Total serum bilirubin \< 1.5 x upper limit of normal (ULN), unless due to Gilbert's syndrome, hemolysis or the underlying leukemia approved by the PI 2. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \< 3 x ULN, unless due to the under…
Given by IV
Given by PO
Given by PO
Arctuva estimate
Verify or correct the compensation shown for this listing.